Comparison · NCT00322452-8341cfe3
Gefitinib vs Carboplatin/Paclitaxel: Diarrhoea
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Gefitinib vs Carboplatin/Paclitaxel: Diarrhoea. Trial comparisons, record NCT00322452-8341cfe3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00322452-8341cfe3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.451 | 0.412 | 0.491 | wilson | |
| Risk in group 2 | 0.217 | 0.186 | 0.252 | wilson | |
| Risk difference, group 1 minus group 2 | 0.234 | 0.182 | 0.285 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.08 | 1.74 | 2.48 | log | |
| Odds ratio, group 1 over group 2 | 2.96 | 2.3 | 3.82 | log | |
| Number needed to treat, for one more participant with the outcome on Gefitinib than on Carboplatin/Paclitaxel | 4.27 | 3.51 | 5.51 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Gefitinib | Gefitinib 250mg daily | 274 | 607 | OG000 |
| Group 2 | Carboplatin/Paclitaxel | Carboplatin AUC 5.0 or 6.0 and Paclitaxel 200 mg/m\^2 doublet chemotherapy every 3 weeks | 128 | 589 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Diarrhoea
- Description
Number of patients with a diarrhoea event. Based on the evaluable-for-safety population, which included all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel)
- Time frame
Includes events that occurred whilst a patient was receiving first-line randomized treatment: defined as date of first dose to date of last dose +1 day for gefitinib, and date of first infusion to date of last infusion + 21 days for carboplatin/paclitaxel
- Population
Analysis was carried out on the Evaluable-for-safety (EFS) population. The EFS population is a subset of the ITT population which includes all patients who received at least 1 dose of study medication (gefitinib, or carboplatin or paclitaxel).
Source ClinicalTrials.gov
Trial
- Title
- First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia
- NCT number
- NCT00322452
- Phases
- PHASE3
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Gefitinib, Carboplatin, Paclitaxel
- Lead sponsor
- AstraZeneca
- Results first posted
- 2010-05-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00322452?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00322452-8341cfe3